BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 16167079)

  • 1. Proton beam therapy and iris neovascularisation in uveal melanoma.
    Boyd SR; Gittos A; Richter M; Hungerford JL; Errington RD; Cree IA
    Eye (Lond); 2006 Jul; 20(7):832-6. PubMed ID: 16167079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iris and anterior chamber angle neovascularization after iodine 125 brachytherapy for uveal melanoma.
    Detorakis ET; Engstrom RE; Wallace R; Straatsma BR
    Ophthalmology; 2005 Mar; 112(3):505-10. PubMed ID: 15745782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proton beam therapy for iris melanomas.
    Lumbroso-Le Rouic L; Delacroix S; Dendale R; Levy-Gabriel C; Feuvret L; Noel G; Plancher C; Nauraye C; Garcia P; Calugaru V; Asselain B; Desjardins L
    Eye (Lond); 2006 Nov; 20(11):1300-5. PubMed ID: 16294207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proton beam therapy for iris melanoma: a review of 15 cases.
    Rundle P; Singh AD; Rennie I
    Eye (Lond); 2007 Jan; 21(1):79-82. PubMed ID: 16410818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Posterior uveal melanoma treated with I-125 brachytherapy or primary enucleation.
    Krohn J; Monge OR; Skorpen TN; Mørk SJ; Dahl O
    Eye (Lond); 2008 Nov; 22(11):1398-403. PubMed ID: 17585309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conservation treatment of the eye: Conformal proton reirradiation for recurrent uveal melanoma.
    Marucci L; Lane AM; Li W; Egan KM; Gragoudas ES; Adams JA; Collier JM; Munzenrider JE
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1018-22. PubMed ID: 16376492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravitreal bevacizumab for iris neovascularization following proton beam irradiation for choroidal melanoma.
    Yeung SN; Paton KE; Waite C; Maberley DA
    Can J Ophthalmol; 2010 Jun; 45(3):269-73. PubMed ID: 20379286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of vascular endothelial growth factor a, matrix metalloproteinase 9 and extravascular matrix patterns in iris and ciliary body melanomas.
    Sahin A; Kiratli H; Tezel GG; Soylemezoglu F; Bilgic S
    Ophthalmic Res; 2007; 39(1):40-4. PubMed ID: 17164576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ocular complications after iodine brachytherapy for large uveal melanomas.
    Puusaari I; Heikkonen J; Kivelä T
    Ophthalmology; 2004 Sep; 111(9):1768-77. PubMed ID: 15350335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proton beam radiotherapy of iris melanoma.
    Damato B; Kacperek A; Chopra M; Sheen MA; Campbell IR; Errington RD
    Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):109-15. PubMed ID: 16111578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Posterior uveal melanoma in young patients treated with proton beam therapy.
    Vavvas D; Kim I; Lane AM; Chaglassian A; Mukai S; Gragoudas E
    Retina; 2010 Sep; 30(8):1267-71. PubMed ID: 20224468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corneoscleral necrosis after episcleral Au-198 brachytherapy of uveal melanoma.
    Chaudhry IA; Liu M; Shamsi FA; Arat YO; Shetlar DJ; Boniuk M
    Retina; 2009 Jan; 29(1):73-9. PubMed ID: 18728617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metastatic melanoma in the eye and orbit.
    Zografos L; Ducrey N; Beati D; Schalenbourg A; Spahn B; Balmer A; Othenin-Girard CB; Chamot L; Egger E
    Ophthalmology; 2003 Nov; 110(11):2245-56. PubMed ID: 14597536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proton beam therapy for the treatment of uveal melanoma in Scotland.
    Macdonald EC; Cauchi P; Kemp EG
    Br J Ophthalmol; 2011 Dec; 95(12):1691-5. PubMed ID: 21216794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular endothelial growth factor is elevated in ocular fluids of eyes harbouring uveal melanoma: identification of a potential therapeutic window.
    Boyd SR; Tan D; Bunce C; Gittos A; Neale MH; Hungerford JL; Charnock-Jones S; Cree IA
    Br J Ophthalmol; 2002 Apr; 86(4):448-52. PubMed ID: 11914216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ruthenium brachytherapy for uveal melanoma, 1979-2003: survival and functional outcomes in the Swedish population.
    Bergman L; Nilsson B; Lundell G; Lundell M; Seregard S
    Ophthalmology; 2005 May; 112(5):834-40. PubMed ID: 15878063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eye-wall resection.
    Char DH; Miller T; Crawford JB
    Trans Am Ophthalmol Soc; 2000; 98():153-9; discussion 159-61. PubMed ID: 11190019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proton beam radiotherapy for uveal melanoma: results of Curie Institut-Orsay proton therapy center (ICPO).
    Dendale R; Lumbroso-Le Rouic L; Noel G; Feuvret L; Levy C; Delacroix S; Meyer A; Nauraye C; Mazal A; Mammar H; Garcia P; D'Hermies F; Frau E; Plancher C; Asselain B; Schlienger P; Mazeron JJ; Desjardins L
    Int J Radiat Oncol Biol Phys; 2006 Jul; 65(3):780-7. PubMed ID: 16647221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uveal melanoma: management and outcome of patients with extraocular spread.
    Bellmann C; Lumbroso-Le Rouic L; Levy C; Plancher C; Dendale R; Sastre-Garau X; Asselain B; Desjardins L
    Br J Ophthalmol; 2010 May; 94(5):569-74. PubMed ID: 19965816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proton therapy of uveal melanomas in Berlin. 5 years of experience at the Hahn-Meitner Institute.
    Höcht S; Bechrakis NE; Nausner M; Kreusel KM; Kluge H; Heese J; Heufelder J; Cordini D; Homeyer H; Fuchs H; Martus P; Foerster MH; Wiegel T; Hinkelbein W
    Strahlenther Onkol; 2004 Jul; 180(7):419-24. PubMed ID: 15241529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.